3 cheap blue chips for December

Are these Footsie favourites now unmissable bargains?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Value is subjective. Nevertheless, most Fools would agree that it can be a good idea to buy shares trading on price weakness so long as a company’s long-term prospects haven’t changed. Given this, let’s look at three companies in the market’s top tier that look like decent picks today.

Priced to go?

After rising sharply to a peak of 5,220p following June’s referendum result, shares in FTSE 100 pharmaceutical giant, Astrazeneca (LSE: AZN) have now fallen 22% over the last few months. This follows a disappointing set of Q3 results and ongoing concerns about its ability to generate sufficient numbers of new treatments to battle its patent cliff. Not even Hilary Clinton’s failure to capture the White House and implement price restrictions on the drug industry has been enough to stop some investors heading for the exits.

Notwithstanding these issues, shares in Astrazencea look fairly cheap right now on a price-to-earnings (P/E) ratio of just 12. As long as things do improve (earnings per share are expected to grow by 20% and 23% over the next two years), there’s also a relatively safe yield of 5.4% on offer. That’s an awful lot more than you’ll get from any savings account.

Ad appeal

This one dipped almost 3% yesterday on news that the US Justice Department is investigating claims that advertising companies are involved in rigging the bidding process for contracts on commercials by promoting their own in-house production units. But I still think that WPP (LSE: WPP) remains a decent choice for those craving hassle-free stocks for their portfolios. Let’s not forget that this is a company that managed to more than double earning per share between 2010 and 2015.

With a forecast P/E of 13, a fully-covered 3.7% yield pencilled-in for next year and Martin Sorrell at the helm, now could be a great opportunity to grab a slice of the resilient FTSE 100 constituent.

Finally, there’s Sky (LSE: SKY). Like Astrazeneca, its shares have been on a downward trajectory over the last year, falling 27% to today’s price of 786p. Nevertheless, with details of new product launches, a 7% increase in sales (compared to Q1 in 2015) and 100,000 new customers, October’s positive Q1 results suggest this fall may be overdone.

With a P/E of just over 13, I’d say that shares in Sky are fairly priced, despite the increased competition it faces from companies like BT. A forecast yield of just under 4.5% for 2017 also looks safe as long as the company can continue to build on the aforementioned figures.

Know thyself

Ultimately, no one knows what the future will bring. Just ask investors in quality spread betting firms like IG Index and CMC Markets how their week is going. 

Although Astrazeneca, WPP and Sky all look tempting at the current time, this isn’t to say that their shares prices couldn’t sink lower given the unpredictable nature of the markets. This is why it’s so important for each and every Foolish investor to consider their tolerance to risk, financial goals and investing horizon before buying a slice of any company.

Thankfully, the multinational nature of all of the above means that they’re not dependent on any one market. This is particularly important given the uncertain political and economic climate we’ve endured in 2016 and — given next year’s French and German elections — that looks likely to continue well into 2017.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Sky. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 super-safe dividend shares I’d buy to target a £1,380 passive income!

Looking to maximise your chances of making a large passive income? These FTSE 100 and FTSE 250 dividend shares might…

Read more »

Investing Articles

I’ve just made a huge decision about my Scottish Mortgage shares!

Harvey Jones has done pretty well after buying Scottish Mortgage shares a year ago but the closer he examines the…

Read more »

Investing Articles

These top passive income stocks all go ex-dividend in October!

Paul Summers has been running the rule on some brilliant passive income stocks, all of which have ex-dividend deadlines coming…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing For Beginners

2 Warren Buffett-type stocks in the UK’s FTSE 100 index worth a look today

Warren Buffett likes to invest in high-quality companies. He also likes to buy when valuations are attractive and he can…

Read more »

artificial intelligence investing algorithms
Growth Shares

The next industrial revolution has begun. Here are 3 growth stocks at its heart

Edward Sheldon believes these three growth stocks will do well as the AI industry grows and the world becomes more…

Read more »

Investing Articles

Given the current economic climate, is there value to be found in UK penny stocks?

Our writer evaluates the prospects of two promising penny stocks on the London Stock Exchange. They each have a compelling…

Read more »

Investing Articles

With yields at 9%+, I expect even more from these FTSE 100 dividend stocks

I'd thought FTSE 100 yields might be declining by now, as the stock market starts to gain. Can these big…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 risky shares for investors to consider buying

It’s important to consider what could go wrong when working out which shares to buy. But sometimes the potential rewards…

Read more »